Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
AstraZeneca lifts 2024 outlook after Q3 beat, doubles down on US investments
Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time this year on Tuesday, helped by strong demand for its cancer and rare diseases medicines, after third-quarter results beat estimates.
AstraZeneca Raises Outlook on Earnings, Sales Beat
AstraZeneca
AZN0.83%increase; green up pointing triangle raised its full-year guidance after third-quarter revenue and core earnings per share topped analysts’ expectations. The Anglo-Swedish pharmaceutical giant said Tuesday that it now expects its 2024 ...
Strong results for AstraZeneca as 2024 earnings forecast rises
Profits have risen at British pharmaceutical company AstraZeneca, leading to an improved forecast for the year as a whole. The multinational reported third-quarter profit of $1.43 billion compared to $1.
AstraZeneca lifts 2024 revenue and profit forecast
Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time in less than four months on Tuesday, helped by resilient demand for its cancer and rare diseases medicines. The London-listed company now expects 2024 revenue and core earnings per share to grow by high teens percentage,
13h
on MSN
AstraZeneca Expands U.S. Investment Plan
The pharmaceutical giant raised its full-year guidance after third-quarter revenue and core earnings per share topped ...
MM&M
8h
AstraZeneca: New drug data, promising earnings and a $3.5B R&D investment
AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...
STAT
15h
Pharmalittle: We’re reading about 23andMe retrenching, AstraZeneca reworking cancer drug plans, and more
In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...
Benzinga.com
15h
AstraZeneca Lifts 2024 Forecast On Better Than Expected Q3 Performance, Says It Takes China Investigations 'Very Seriously'
AstraZeneca
's Q3 sales rose 18% YoY to $13.6 billion Adjusted EPADS hit $1.04, exceeding expectations. U.S. investment of ...
BioSpace
12h
AstraZeneca Dodges China Questions While Raising 2024 Outlook With Strong Q3 Sales
The U.K. drugmaker also announced plans to drop another $2 billion on expanding its R&D and manufacturing footprint in the ...
STAT
19h
AstraZeneca, Daiichi Sankyo change strategy on closely watched cancer drug
LONDON — AstraZeneca said Tuesday it has had to resubmit a closely watched medicine for U.S. approval in a different form of ...
20h
on MSN
AstraZeneca lifts 2024 revenue and profit forecast after Q3 beat
Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time this year on Tuesday, helped by strong ...
FiercePharma
19h
AstraZeneca CEO defends corporate oversight, $80B revenue target amid China probes
Despite China’s investigations into insurance fraud, allegedly illegal importation of unapproved drugs and improper ...
14h
AstraZeneca reports Q3 core EPS $2.08, consensus $1.03
Reports Q3 revenue $13.6B, consensus $13.09B. Pascal Soriot, CEO, AstraZeneca (AZN), commenting on the results said: “Our company has ...
The Washington Post
19h
Astrazeneca: Q3 Earnings Snapshot
CAMBRIDGE, Britain — CAMBRIDGE, Britain —
Astrazeneca
PLC (AZN) on Tuesday reported third-quarter earnings of $1.43 billion. On a per-share basis, the Cambridge, Britain-based company said it had ...
12h
on MSN
AstraZeneca says detained China head has lawyer, but company still in dark
AstraZeneca's China president Leon Wang, who was detained last month by Chinese authorities, is in touch with a lawyer but ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
China
Q3
United States
London
Tezspire
Feedback